After careful review of available studies from the last several influenza seasons, NACI has revised its recommendations on the use of influenza vaccine in children 2-17 years of age:

1. In children without contraindications to the vaccine, any of the following vaccines can be used: quadrivalent live attenuated influenza vaccine (LAIV), quadrivalent inactivated influenza vaccine (QIV) or trivalent inactivated influenza vaccine (TIV).
2. The current evidence does not support a recommendation for the preferential use of LAIV in children and adolescents 2-17 years of age.
Given the burden of influenza B disease in children and the potential for lineage mismatch between the predominant circulating strain of influenza B and the strain in a trivalent vaccine, NACI continues to recommend that a quadrivalent formulation of influenza vaccine be used in children and adolescents 2-17 years of age. If a quadrivalent vaccine is not available, TIV should be used.

Recommendation Americas Canada